SAN FRANCISCO, Feb. 13, 2013 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2012 on Thursday, February 28, 2013, after the close of U.S.-based financial markets. Howard Robin , president and chief executive officer, will host a conference call to review these results beginning at 5:00 p.m. Eastern Time (ET)/2:00 p.m. Pacific Time (PT).
The press release and a live audio-only Webcast of the conference call can be accessed through a link that is posted on the home page and Investor Relations section of the Nektar website: http://www.nektar.com. The web broadcast of the conference call will be available for replay through Friday, March 29, 2013.
To access the conference call, follow these instructions:
Dial: (877) 881-2183 (U.S.); (970) 315-0453 (international)
Passcode: 98224860 (Nektar Therapeutics is the host)
In the event that any non-GAAP financial measure is discussed on the conference call that is not described in the press release, or explained on the conference call, related information will be made available on the Investor Relations page at the Nektar website as soon as practical after the conclusion of the conference call.
Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms. Nektar has a robust R&D pipeline of potentially high-value therapeutics in oncology, pain and other therapeutic areas. In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for naloxegol (NKTR-118), an inve
|SOURCE Nektar Therapeutics|
Copyright©2012 PR Newswire.
All rights reserved